CIS Display™ vs. Phage Display: Choosing the Right Fit for VHH or Peptide Discovery Choosing the right display technology is a critical decision in therapeutic and diagnostic discovery procedures. This article compares CIS Display™ with Phage Display, focusing on...
NGS in Antibody Discovery: How Deep is Your Sequence? Next-generation sequencing (NGS) has revolutionized antibody discovery by enabling high-depth analysis of diverse libraries, surpassing the limitations of traditional methods like Sanger sequencing. This article...
Unlocking Hard-to-Drug Targets: How VHH Antibodies Overcome Drug Discovery Barriers For decades, certain drug targets have been labeled as “undruggable” due to their complex structures, lack of accessible binding sites, or dynamic conformational changes....
A Competitive and Ethical Future in Discovery Pharmaceutical and biotech R&D is undergoing a notable shift in how therapeutic antibodies are discovered. Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise...
Isogenica named in Business Weekly’s Ones2Watch In Q1 2025, Business Weekly published its latest Killer50 showcase – a long-standing benchmark for innovation in UK life sciences Recognition in a Difficult Quarter In Q1 2025, Business Weekly...
Building the next generation of precision oncology medicines Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development...
